ClinicalTrials.gg
CompletedNCT05569174UnchAINUpdated Jan 23, 2026Results posted

Study of Efficacy and Safety of AIN457/Secukinumab in Patients With Rotator Cuff Tendinopathy

A Phase 3 interventional study of Secukinumab and Placebo in Tendinopathy, sponsored by Novartis Pharmaceuticals. Completed at 19 sites in Germany. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-01-23.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
62
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 11 studies in Tendinopathy with a site in Germany — 2 open to participants now, 2 under way, none of them phase 3. Tendinopathy · Germany.

Enrollment
6th of 10
62 · median 66
Started
2022
the only one that year
Phase 3
3 of 11
none open now
Registered
8th of 11
by date
Lead sponsor
3 of 11
Novartis Pharmaceuticals

Among the 11 studies in Tendinopathy with a site in Germany, this one is the 6th largest by enrollment of the 10 interventional ones that give a count, is the only one that started in 2022, is one of 3 in phase 3, and was the 8th registered.

Tendinopathy

397 studies on the registry are indexed under Tendinopathy; 77 are open to participants now.

Browse Tendinopathy studies →

Open to participants now

2 of the 11 studies in Tendinopathy with a site in Germany are open now. Recruiting first, the newest first:

All 2 open studies →

A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →

Who these studies take

Of the 47 Tendinopathy studies recruiting now, 17 (36%) set no upper age limit and 23 (49%) stop at 75 or younger; 1 takes children under 18; 7 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies in Tendinopathy with a site in Germany, or all of them as a file.
02

Study summary

The purpose of this study was to investigate the efficacy and safety of secukinumab subcutaneously (s.c.) compared to placebo in adult patients with moderate to severe rotator cuff tendinopathy and failure to conventional therapy.

Read the detailed description

This was a randomized, double-blind, placebo-controlled, parallel-group, multicenter, Phase IIIb, 24-week study to investigate the superior efficacy of secukinumab and safety in participants with rotator cuff tendinopathy.

Secukinumab 300 mg s.c. was compared to placebo (both arms in combination with patient individualized conventional therapy) in relieving clinical symptoms at Week 24.

The study consisted of a screening period up to 6 weeks, a 2-week run-in period, a 12-week treatment period and a 12-week follow-up period. Treatment and follow-up periods were blinded. Participants who met the eligibility criteria at screening continued to the run-in period and were randomized. In the run-in period, participants performed 2 weeks of home-based standardized physiotherapy.

03

Conditions studied

  • Tendinopathy

Browse trials for

Keywords

  • shoulder
  • rotator cuff
  • IL-17A-Ab
  • AIN457X
  • Impingement syndrome
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Signed had to be obtained prior to participation in the study.
  • Males and non-pregnant, non-nursing females were between 18 and 65 years of age.
  • Rotator cuff tendinopathy (unilateral) was present with a positive "Painful Arc Test" on examination.
  • Symptoms had been present for at least 6 weeks but not more than 6 months at Baseline.
  • Moderate to severe rotator cuff tendinopathy was demonstrated by all of the following criteria:

    1. WORC score was ≤ 40 at Baseline.
    2. NRS pain score was ≥ 5 at Baseline and for at least 3 days of the 7 days prior to Baseline.
    3. Nocturnal pain occurred at least 4 out of the 7 days in the week prior to Baseline.
  • Patients had failed at least 8 weeks of conventional therapy prior to Baseline: inadequate response to NSAIDs and/or paracetamol and physiotherapy; or intolerance to NSAIDs and/or paracetamol.

Exclusion criteria

Exclusion Criteria:

  • Greater than 50% partial thickness tear had been established by MRI or ultrasound during assessment in the Run-in phase.
  • Patients were expected to require treatment throughout the trial duration at Baseline (e.g., systemic, intramuscular, local injections in shoulder).
  • Previous surgery, or plans for surgery, during the study period, in the affected shoulder.
  • Rheumatologic and chronic inflammatory diseases, including but not limited to inflammatory bowel disease, polymyalgia rheumatica (PMR), PsA, axSpA and rheumatoid arthritis (RA), fibromyalgia or - severe pain disorder unrelated to the target shoulder.
  • Rheumatoid factor (RF) and anti-cyclic citrullinated peptide (anti-CCP) antibodies were positive at Screening.
  • History of adhesive capsulitis/frozen shoulder or calcification in the tendon (in affected or contralateral shoulder) had been confirmed clinically or by medical imaging.
  • Symptomatic osteoarthritis of the shoulder (glenohumeral, acromioclavicular) in affected or contralateral shoulder had been confirmed by medical imaging.
  • Patients had traumatic rupture that would have been considered eligible for surgery for repair of cuff tear.
  • Neurological conditions including but not limited to cervical radiculopathy, which in the opinion of the investigator could have explained the patient's symptoms.
  • Any intra-articular/subacromial glucocorticoid treatment had occurred within 12 weeks prior to Baseline or more than 2 injections for the current tendinopathy.
  • Any oral, intramuscular or i.v. glucocorticoid treatment had occurred 12 weeks prior to Baseline or during the current tendinopathy, whichever was longer.
  • Previous rich plasma (PRP) injections or fluoroquinolone/quinolone antibiotics had occurred within 12 weeks prior to Baseline or during the current tendinopathy, whichever was longer.
  • Neuromuscular or primary/secondary muscular deficiency had limited the ability to perform functional measurement (e.g., shoulder strength test).
  • Previous hyaluronic injections had occurred within 12 weeks prior to Baseline or during the current tendinopathy, whichever was longer.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
62 participants (actual)

Study arms

  • Experimental
    Secukinumab

    Participants received 300 mg of secukinumab s.c. for 12 weeks

    Drug: Secukinumab

  • Placebo comparator
    Placebo

    Participants received placebo s.c. for 12 weeks

    Other: Placebo

Interventions

  • Secukinumab 300 mg s.c for 12 weeks in a pre-filled syringe (PFS)

    Also known as: AIN457

  • OtherPlacebo

    Placebo to match secukinumab s.c. for 12 weeks in a PFS

06

What researchers measure

Primary outcomes

  1. Change From Baseline in the Western Ontario Rotator Cuff (WORC) Patient Reported Outcome (PRO) Percentage Score at Week 24

    The WORC Index consisted of 21 items divided into 5 Domains: Physical Symptoms (6 items), Sport/Recreation (4 items), Work Function (4 items), Lifestyle Function (4 items) and Emotional Function (3 items). Each of the 21 items in the WORC was rated using a visual analogue scale (VAS) ranging from 0 (no impact on quality of life) to 100 (worst possible impact). Thus, the total score ranged from 0 to 2100 points. The score was reported as a percentage of normal by subtracting the total score from 2100, dividing by 2100, and multiplying by 100. Total final WORC percentage scores ranged from 0%, the lowest functional status level, to 100%, the highest functional status level. Change from baseline in the WORC percentage total score was assessed at Week 24. A positive change from baseline indicated an improvement.

    Time frame: Baseline, Week 24

Secondary outcomes

  1. Change From Baseline in the WORC Percentage Sub-scores at Week 24

    The WORC Index consisted of 21 items divided into 5 Domains: Physical Symptoms (6 items), Sport/Recreation (4 items), Work Function (4 items), Lifestyle Function (4 items) and Emotional Function (3 items). Each of the 21 items in the WORC was rated using a VAS ranging from 0 (no impact on quality of life) to 100 (worst possible impact). Each subdomain score was calculated as a percentage of normal function, ranging from 0% (worst condition) to 100% (best condition). Change from baseline in the WORC Index percentage sub-domain score was assessed at Week 24. A positive change from baseline indicated an improvement

    Time frame: Baseline, Week 24

  2. Change From Baseline in Participant's Global Assessment of Disease Activity Score at Week 24

    The participant's global assessment of disease activity was performed using 100 mm VAS ranging from 0="no activity" to 100= "most active", after the question " Please indicate with a vertical mark ( \| ) through the horizontal line the global activity of your disease in the last 24 hours". Change from baseline in the participant's global assessment of disease activity score was assessed at Week 24. A negative change from baseline indicated improvement

    Time frame: Baseline, Week 24

  3. Change From Baseline in Short Form 36 (SF-36v2) Score at Week 24

    The SF-36 Health Survey was a validated questionnaire assessing health-related quality of life. Participants completed the survey throughout the study, reflecting their health status over the previous 4 weeks. It consisted of eight subscales that were scored individually; and two overall summary scores, the Physical Component Summary (PCS) and the Mental Component Summary (MCS). Component summary scores (PCS and MCS) were derived from weighted combinations of the eight subscales. Each domain and component summary score ranged from 0 to 100, with higher scores indicating better quality of life. Change from baseline to Week 24 in all subscale and summary scores was assessed, where a positive change indicated improvement.

    Time frame: Baseline, Week 24

  4. Change From Baseline in Quick Disability of the Arm, Shoulder and Hand (DASH) Questionnaire Score at Week 24

    The QuickDASH was an abbreviated form of the DASH. The QuickDASH Index was self-administered and used 11 items to measure physical function and symptoms in participants with any or multiple musculoskeletal disorders of the upper limb. It had a recall period of 1 week. Each item of the QuickDASH had five response options. The raw score was calculated as the sum of responses, converted to an average, and rescaled to a total score ranging from 0 (no disability) to 100 (most severe disability) Change from baseline to Week 24 was assessed. A negative change from baseline indicated improvement.

    Time frame: Baseline, Week 24

  5. Change From Baseline in the Numeric Rating Scale (NRS) Pain Score at Week 24

    The score for pain was assessed by using an 11-point NRS ranging from 0 "no pain at all" to 10 "worst possible pain", after the question "On a numeric scale of 0-10 where would you rate your pain at this time". Change from baseline to Wek 24 was assessed. A negative change from baseline indicated improvement

    Time frame: Baseline, Week 24

  6. Change From Baseline in EuroQol 5 Dimensions- 5 Levels (EQ-5D-5L) at Week 24- Total Score

    The EQ-5D-5L was a standardized instrument used to evaluate patients' overall health-related quality of life (QoL). It consisted of two components: the descriptive system and the EQ visual analogue scale (EQ VAS). The descriptive system assessed five dimensions of health: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension was rated on five levels, from 1 (no problems) to 5 (extreme problems). These ratings were combined to generate a composite health index, which could be converted into a single summary health utility score using published value sets. Total scores ranged from 0 to 1, with lower scores indicating greater health impairment. Changes in total scores from baseline to Week 24 were analyzed, with positive changes indicating improvement in health-related quality of life.

    Time frame: Baseline, Week 24

  7. Change From Baseline in EuroQol 5 Dimensions- 5 Levels (EQ-5D-5L) at Week 24- EQ VAS

    The EQ-5D-5L was a standardized instrument used to evaluate patients' overall health-related quality of life (QoL). It consisted of two components: the descriptive system and the EQ visual analogue scale (EQ VAS). The EQ VAS captured the respondent's self-rated health on a vertical scale ranging from 0 (worst imaginable health) to 100 (best imaginable health). Changes in EQ VAS scores from baseline to Week 24 were analyzed, with positive changes indicating improvement in health-related quality of life.

    Time frame: Baseline, Week 24

07

Results

Posted Dec 2, 2025

Participant flow

Patients were randomized in 19 study sites across Germany

Participant flow — Overall Study
MilestoneSecukinumabPlacebo
Started3032
Completed3027
Not completed05
Withdrew: Adverse event01
Withdrew: Lack of compliance01
Withdrew: Withdrawal of consent01
Withdrew: Participant wish01
Withdrew: Lost to follow-up01

Outcome measures

PrimaryChange From Baseline in the Western Ontario Rotator Cuff (WORC) Patient Reported Outcome (PRO) Percentage Score at Week 24

The WORC Index consisted of 21 items divided into 5 Domains: Physical Symptoms (6 items), Sport/Recreation (4 items), Work Function (4 items), Lifestyle Function (4 items) and Emotional Function (3 items). Each of the 21 items in the WORC was rated using a visual analogue scale (VAS) ranging from 0 (no impact on quality of life) to 100 (worst possible impact). Thus, the total score ranged from 0 to 2100 points. The score was reported as a percentage of normal by subtracting the total score from 2100, dividing by 2100, and multiplying by 100. Total final WORC percentage scores ranged from 0%, the lowest functional status level, to 100%, the highest functional status level. Change from baseline in the WORC percentage total score was assessed at Week 24. A positive change from baseline indicated an improvement.

Time frame:
Baseline, Week 24
Reported as:
Mean · Score on a Scale
Change From Baseline in the Western Ontario Rotator Cuff (WORC) Patient Reported Outcome (PRO) Percentage Score at Week 24
Score on a ScaleSecukinumabPlacebo
Change From Baseline in the Western Ontario Rotator Cuff (WORC) Patient Reported Outcome (PRO) Percentage Score at Week 2455.7 ± 28.146.8 ± 26.9
SecondaryChange From Baseline in the WORC Percentage Sub-scores at Week 24

The WORC Index consisted of 21 items divided into 5 Domains: Physical Symptoms (6 items), Sport/Recreation (4 items), Work Function (4 items), Lifestyle Function (4 items) and Emotional Function (3 items). Each of the 21 items in the WORC was rated using a VAS ranging from 0 (no impact on quality of life) to 100 (worst possible impact). Each subdomain score was calculated as a percentage of normal function, ranging from 0% (worst condition) to 100% (best condition). Change from baseline in the WORC Index percentage sub-domain score was assessed at Week 24. A positive change from baseline indicated an improvement

Time frame:
Baseline, Week 24
Reported as:
Mean · Score on a Scale
Change From Baseline in the WORC Percentage Sub-scores at Week 24
Score on a ScaleSecukinumabPlacebo
Physical symptom score48.8 ± 31.240.0 ± 25.0
Sports and recreation51.8 ± 30.944.0 ± 30.6
Work59.7 ± 32.049.9 ± 30.5
Lifestyle59.5 ± 27.352.9 ± 26.4
Emotional function64.2 ± 23.654.3 ± 31.5
SecondaryChange From Baseline in Participant's Global Assessment of Disease Activity Score at Week 24

The participant's global assessment of disease activity was performed using 100 mm VAS ranging from 0="no activity" to 100= "most active", after the question " Please indicate with a vertical mark ( \| ) through the horizontal line the global activity of your disease in the last 24 hours". Change from baseline in the participant's global assessment of disease activity score was assessed at Week 24. A negative change from baseline indicated improvement

Time frame:
Baseline, Week 24
Reported as:
Mean · Score on a scale
Change From Baseline in Participant's Global Assessment of Disease Activity Score at Week 24
Score on a scaleSecukinumabPlacebo
Change From Baseline in Participant's Global Assessment of Disease Activity Score at Week 24-46.4 ± 36.6-18.5 ± 37.2
SecondaryChange From Baseline in Short Form 36 (SF-36v2) Score at Week 24

The SF-36 Health Survey was a validated questionnaire assessing health-related quality of life. Participants completed the survey throughout the study, reflecting their health status over the previous 4 weeks. It consisted of eight subscales that were scored individually; and two overall summary scores, the Physical Component Summary (PCS) and the Mental Component Summary (MCS). Component summary scores (PCS and MCS) were derived from weighted combinations of the eight subscales. Each domain and component summary score ranged from 0 to 100, with higher scores indicating better quality of life. Change from baseline to Week 24 in all subscale and summary scores was assessed, where a positive change indicated improvement.

Time frame:
Baseline, Week 24
Reported as:
Mean · Score on a Scale
Change From Baseline in Short Form 36 (SF-36v2) Score at Week 24
Score on a ScaleSecukinumabPlacebo
Physical component summary9.4 ± 9.19.7 ± 7.9
Mental component summary8.0 ± 10.76.3 ± 11.9
General health3.0 ± 8.53.9 ± 10.6
Vitality8.3 ± 9.97.7 ± 11.0
Social functioning8.3 ± 10.18.2 ± 10.9
Role emotional11.5 ± 13.15.8 ± 14.5
Mental health7.6 ± 10.09.1 ± 10.9
Physical function8.8 ± 9.58.6 ± 6.4
Role-physical9.9 ± 10.39.3 ± 10.9
Bodily pain16.2 ± 10.215.1 ± 9.2
SecondaryChange From Baseline in Quick Disability of the Arm, Shoulder and Hand (DASH) Questionnaire Score at Week 24

The QuickDASH was an abbreviated form of the DASH. The QuickDASH Index was self-administered and used 11 items to measure physical function and symptoms in participants with any or multiple musculoskeletal disorders of the upper limb. It had a recall period of 1 week. Each item of the QuickDASH had five response options. The raw score was calculated as the sum of responses, converted to an average, and rescaled to a total score ranging from 0 (no disability) to 100 (most severe disability) Change from baseline to Week 24 was assessed. A negative change from baseline indicated improvement.

Time frame:
Baseline, Week 24
Reported as:
Mean · Score on a Scale
Change From Baseline in Quick Disability of the Arm, Shoulder and Hand (DASH) Questionnaire Score at Week 24
Score on a ScaleSecukinumabPlacebo
Change From Baseline in Quick Disability of the Arm, Shoulder and Hand (DASH) Questionnaire Score at Week 24-34.1 ± 23.7-33.5 ± 24.6
SecondaryChange From Baseline in the Numeric Rating Scale (NRS) Pain Score at Week 24

The score for pain was assessed by using an 11-point NRS ranging from 0 "no pain at all" to 10 "worst possible pain", after the question "On a numeric scale of 0-10 where would you rate your pain at this time". Change from baseline to Wek 24 was assessed. A negative change from baseline indicated improvement

Time frame:
Baseline, Week 24
Reported as:
Mean · Score on a Scale
Change From Baseline in the Numeric Rating Scale (NRS) Pain Score at Week 24
Score on a ScaleSecukinumabPlacebo
Change From Baseline in the Numeric Rating Scale (NRS) Pain Score at Week 24-4.5 ± 2.8-4.6 ± 2.4
SecondaryChange From Baseline in EuroQol 5 Dimensions- 5 Levels (EQ-5D-5L) at Week 24- Total Score

The EQ-5D-5L was a standardized instrument used to evaluate patients' overall health-related quality of life (QoL). It consisted of two components: the descriptive system and the EQ visual analogue scale (EQ VAS). The descriptive system assessed five dimensions of health: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension was rated on five levels, from 1 (no problems) to 5 (extreme problems). These ratings were combined to generate a composite health index, which could be converted into a single summary health utility score using published value sets. Total scores ranged from 0 to 1, with lower scores indicating greater health impairment. Changes in total scores from baseline to Week 24 were analyzed, with positive changes indicating improvement in health-related quality of life.

Time frame:
Baseline, Week 24
Reported as:
Mean · Score on a Scale
Change From Baseline in EuroQol 5 Dimensions- 5 Levels (EQ-5D-5L) at Week 24- Total Score
Score on a ScaleSecukinumabPlacebo
Change From Baseline in EuroQol 5 Dimensions- 5 Levels (EQ-5D-5L) at Week 24- Total Score0.265 ± 0.2260.342 ± 0.228
SecondaryChange From Baseline in EuroQol 5 Dimensions- 5 Levels (EQ-5D-5L) at Week 24- EQ VAS

The EQ-5D-5L was a standardized instrument used to evaluate patients' overall health-related quality of life (QoL). It consisted of two components: the descriptive system and the EQ visual analogue scale (EQ VAS). The EQ VAS captured the respondent's self-rated health on a vertical scale ranging from 0 (worst imaginable health) to 100 (best imaginable health). Changes in EQ VAS scores from baseline to Week 24 were analyzed, with positive changes indicating improvement in health-related quality of life.

Time frame:
Baseline, Week 24
Reported as:
Mean · Score on a Scale
Change From Baseline in EuroQol 5 Dimensions- 5 Levels (EQ-5D-5L) at Week 24- EQ VAS
Score on a ScaleSecukinumabPlacebo
Change From Baseline in EuroQol 5 Dimensions- 5 Levels (EQ-5D-5L) at Week 24- EQ VAS18.3 ± 36.523.8 ± 27.3

Adverse events

Collected over From start of treatment to end of study, assessed up to approximately 24 weeks. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Secukinumab0/30 (0%)2/30 (6.7%)22/30 (73.3%)
Placebo0/32 (0%)3/32 (9.4%)24/32 (75%)
Most frequent serious events
Most frequent serious events
EventSecukinumabPlacebo
Oropharyngeal candidiasisInfections and infestations1/300/32
DepressionPsychiatric disorders1/300/32
Vaginal cuff dehiscenceInjury, poisoning and procedural complications0/301/32
Lipase increasedInvestigations0/301/32
Pancreatic neuroendocrine tumourNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/301/32
Occipital lobe strokeNervous system disorders0/301/32
Paradoxical embolismVascular disorders0/301/32
Most frequent other events
Showing 10 of 17
Most frequent other events
EventSecukinumabPlacebo
ArthralgiaMusculoskeletal and connective tissue disorders3/3011/32
HeadacheNervous system disorders8/306/32
NasopharyngitisInfections and infestations5/307/32
COVID-19Infections and infestations4/303/32
Back painMusculoskeletal and connective tissue disorders4/303/32
HypertensionVascular disorders3/302/32
BronchitisInfections and infestations0/303/32
Gastrointestinal infectionInfections and infestations2/300/32
Oral herpesInfections and infestations2/302/32
Respiratory tract infectionInfections and infestations2/300/32

Baseline characteristics

Age, Continuous
Age, Continuous(years)SecukinumabPlaceboTotal
Mean52.3 ± 7.552.1 ± 9.052.2 ± 8.2
Sex: Female, Male
Sex: Female, Male(Participants)SecukinumabPlaceboTotal
Female201535
Male101727
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)SecukinumabPlaceboTotal
Caucasian293160
Black101
Asian011
08

Study locations

19 sites
  • Novartis Investigative Site
    Karlsruhe, Baden-Wurttemberg 76133, Germany
  • Novartis Investigative Site
    Munich, Bavaria 80809, Germany
  • Novartis Investigative Site
    Hanover, Lower Saxony 30159, Germany
  • Novartis Investigative Site
    Halle, Saxony-Anhalt 06120, Germany
  • Novartis Investigative Site
    Bad Doberan, 18209, Germany
  • Novartis Investigative Site
    Berlin, 10787, Germany
  • Novartis Investigative Site
    Berlin, 12627, Germany
  • Novartis Investigative Site
    Cottbus, 03042, Germany
  • Novartis Investigative Site
    Dresden, 01069, Germany
  • Novartis Investigative Site
    Erlangen, 91054, Germany
  • Novartis Investigative Site
    Frankfurt am Main, 60313, Germany
  • Novartis Investigative Site
    Gladbeck, 45968, Germany
  • Novartis Investigative Site
    Hamburg, 20095, Germany
  • Novartis Investigative Site
    Hamburg, 20149, Germany
  • Novartis Investigative Site
    Hamburg, 22415, Germany
  • Novartis Investigative Site
    Heinsberg, 52525, Germany
  • Novartis Investigative Site
    Herne, 44649, Germany
  • Novartis Investigative Site
    Mainz, 55131, Germany
  • Novartis Investigative Site
    Schönebeck, 39218, Germany
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Dec 2022 to primary completion in Dec 2024, 24 months.

Results were first posted in Dec 2025, 11 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 4, 2022
First posted
Oct 6, 2022
StartActual
Dec 2, 2022
Primary completionActual
Dec 18, 2024
CompletionActual
Dec 18, 2024
Results first posted
Dec 2, 2025
Last update
Jan 23, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 23, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05569174
Responsible party
Sponsor
First posted
Oct 6, 2022
Start date
Dec 2, 2022
Primary completion
Dec 18, 2024
Completion
Dec 18, 2024
Results posted
Dec 2, 2025
Last update
Jan 23, 2026

Study contacts

Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Secukinumab

Start the discussion